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Our study has several limitations. For example, infor-
mation on clinical features and outcomes of patients, ex-
cept for death, was unavailable, and we could not deter-
mine prognostic factors for recent JE cases. Because details 
of each patient’s travel history was not identified, we could 
not clearly understand the mechanism of JEV transmission. 
In addition, we do not explore the possible cause of JE re-
emergence. Moreover, although JE incidence was detected 
by the national surveillance system, incidence might be un-
derestimated because the database identified only serologi-
cally confirmed cases.
JE vaccination is presumed to have failed to induce 
lifelong immunity so that older age groups become sus-
ceptible again. Further research is warranted to determine 
the long-term protection against JEV after primary vacci-
nation. Moreover, future studies should address the need 
for booster vaccination for adults to maintain immunity 
against JEV.
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To the Editor: Enterovirus A71 (EV-A71) strains 
circulate worldwide, and numerous outbreaks have been 
reported from Asia, Australia, Europe, and America (1). 
Symptomatic infections range from mild febrile illness or 
characteristic diseases such as hand, foot and mouth dis-
ease to severe neurologic disorders such as meningitis/
encephalitis and acute flaccid paralysis. EV-A71 infections 
are usually asymptomatic and self-limiting but can also 
result in life-threatening complications such as pulmonary 
edema and cause death, predominantly in children <5 years 
of age. On the basis of viral protein 1 (VP1) sequences, 3 
genogroups (A, B, C), including different subgenogroups 
(B0–B5, C1–C5), have been defined (2,3). Additional geno-
groups (D, E, F, G) have been proposed (4,5). In Europe, 
C1 and C2 strains have circulated predominantly within the 
past 2 decades, and recent introduction of C4 strains has 
been reported (6,7). Within subgenogroup C1, a lineage is 
replaced by the subsequent lineage over time (8). 
National enterovirus surveillance (EVSurv) in Ger-
many monitors polio-free status by testing fecal or cere-
brospinal fluid (CSF) samples from hospitalized patients 
with suspected meningitis/encephalitis or acute flaccid pa-
ralysis. Enterovirus typing, using molecular and virologic 
methods, is performed within a laboratory network for 
enterovirus diagnostics. Since 2006, ≈2,500 samples have 
been tested annually; 25%–30% were enterovirus positive. 
Of the typed strains, 0.8%–12.7% were identified as EV-
A71 (2006, 0.8%; 2007, 6.8%; 2008, 0.9%; 2009, 3.4%; 
2010, 12.7%; 2011, 2.3%; 2012, 2.8%; 2013, 8.6%; 2014, 
2.7%), indicating peaks with increased EV-A71 detection 
rates. Molecular characterization based on the VP1 region 
of a subset of EV-A71–positive samples revealed that C2 
was the predominant subgenogroup in Germany from 2006 
to 2014. Subgenogroups B5, C1, and C4 have also been 
identified, but less frequently (online Technical Appendix 
Table 3, http://wwwnc.cdc.gov/EID/article/22/10/16-0357-
Techapp1.pdf). 
In 2015, a total of 419 samples tested enterovirus 
positive within EVSurv. Of these, 43 fecal specimens and 
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Figure. Phylogenetic tree based on complete 
viral protein 1 (VP1) nucleotide sequences of the 
strains identified within the German enterovirus 
surveillance (bold) and a representative set of 
enterovirus A71 strains available from GenBank 
(891 bases, corresponding to nucleotide 
positions 2439–3329 in the prototype BrCr 
ETU22521). The tree was constructed by using 
the neighbor-joining method (Kimura 2-parameter 
model) with 1,000 replicates through MEGA 6.06 
(http://www.megasoftware.net/). Coxsackievirus 
A16 prototype (CAU05876) was used as the 
outgroup. Only bootstrap values >70 are shown. 
Genogroup and subgenogroup assignment, 
GenBank accession number, country and year 
of isolation are provided in the virus names. 
The enlarged subtree includes enterovirus A71 
C1-like strains detected in Germany in 2015. 
Virus names contain strain number, abbreviation 
of federal state, country, and year of isolation. 
BE, Berlin; BB, Brandenburg; DE, Germany; 
MV, Mecklenburg Western Pomerania; NI, 
Lower Saxony; NW, Northrhine-Westphalia; RP, 
Rhineland Palatinate; TH, Thuringia. Scale bars 
indicate nucleotide substitution per site.
1 CSF specimen tested EV-A71 positive (11.2% of the 
typed enteroviruses); these samples were obtained from 
patients with signs of meningitis/encephalitis hospitalized 
in 25 secondary and tertiary care hospitals from 13 of 16 
federal states of Germany. Thirty-six strains were further 
characterized at the National Reference Centre for Polio-
myelitis and Enteroviruses (online Technical Appendix 
Table 2). Seventeen strains were identified as C2 by us-
ing the RIVM Enterovirus Genotyping Tool Version 1.0 
(http://www.rivm.nl/mpf/enterovirus/typingtool) based on 
the VP1 region sequences (9). Sequence analyses of the 
remaining 19 strains revealed highest nucleotide identity 
(90%–93%) with recently circulating C1 strains from Gen-
Bank. Phylogenetic analysis that used the neighbor-joining 
tree algorithm showed separate clustering of these strains 
within the C1 subgenogroup (Figure). In contrast to the 
VP1 tree, phylogenetic analyses based on the 5′ untrans-
lated region (UTR) and the P2 and P3 regions revealed 
different clustering of the German 2015 EV-A71 C1-like 
group (online Technical Appendix Figure). In line with 
these phylogenetic tree topologies, we found highest nu-
cleotide identities to subgenogroup B3 and C2-like strains 
for 5′ UTR (both 90%), whereas P2 and P3 regions showed 
highest nucleotide identity of 82% and 84%, respectively, 
with C4 strains identified in China. We found no specific 
amino acid changes within the conserved major antigenic 
sites of the capsid proteins. However, we observed a V16M 
change in VP1. Few EV-A71 strains (all B1) also carry a 
methionine at this position, including the outbreak strains 
from Bulgaria (1975) and Hungary (1978). Also, we identi-
fied a valine residue at position 262 in VP1. Tee et al. have 
proposed that toggling of amino acids isoleucine and valine 
at this position in recent C1 lineages generates antigenic 
novelty (8). Within the 5′ UTR, a C526U change has been 
proposed to affect replication efficiency (10). All isolates 
belonging to the new EV-A71 C1 variant carried uracil at 
this position. In addition, we found a 2-nucleotide deletion 
within the spacer 2 region between the internal ribosome 
entry site and the coding region, similar to the EV-A71 pro-
totype BrCr and the C2-like strains (GenBank accession 
nos. HM622392, HM622391, JQ280307) (data available 
on request).
Our findings highlight the need for molecular surveil-
lance of enteroviruses to identify new variant strains with 
potential for increased virulence and pathogenicity. One 
limitation of the EVSurv is the lack of detailed clinical 
data because the request form deliberately asks for only 
basic cardinal symptoms justifying the clinical suspicion 
of meningitis/encephalitis or acute flaccid paralysis. Nev-
ertheless, all patients had been hospitalized, suggesting 
severe disease. Besides characteristic symptoms (includ-
ing nuchal rigidity, headache, fever, and vomiting), cere-
bral seizures, myoclonia, ataxia, petechiae, and stomatitis 
were also mentioned for some patients tested for the new 
variant C1-like strains described here. All but 1 patient 
was <5 years of age (online Technical Appendix Table 1). 
Therefore, pediatricians, in particular, should be aware of 
this new recombinant, potentially more pathogenic, strain 
and intensify diagnostic work-ups to better monitor EV-
A71 circulation. In addition to CSF samples, fecal sam-
ples, throat swab specimens, and samples related to other 
clinical prodromes (e.g., vesicle fluids in cases of hand, 
foot and mouth disease) should be obtained. Particular at-
tention should be paid to measures in daycare centers to 
prevent large outbreaks of enterovirus-associated menin-
gitis/encephalitis.
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To the Editor: Tertiary syphilis, including cerebral 
syphilitic gumma, usually occurs >10 years after contract-
ing syphilis (1) and is a rare manifestation since the intro-
duction of penicillin (2). However, progression of syphi-
lis is reported to be faster in HIV-infected patients than 
in those without such infections (3). We report a case of 
cerebral syphilitic gumma in an HIV-1–infected patient for 
whom serum samples obtained as recently as 5 months ear-
lier showed negative results for syphilis.
A 21-year-old man infected with HIV came to the 
AIDS Clinical Center, National Center for Global Health 
and Medicine (Tokyo, Japan), because of a 2-hour loss of 
consciousness. He reported an uncomfortable feeling at the 
back of his head and neck and eye fatigue that lasted for 
1 week. His HIV-1 infection was well-controlled with an 
antiretroviral combination of tenofovir, emtricitabine, and 
dolutegravir. The patient had a CD4 count of 565 cells/mL 
and a viremia level below detectable limits (<20 copies/
mL). He was not using any other medications. 
At examination, his vital signs were within refer-
ence ranges. Apart from a tongue bite, physical and 
neurologic examinations showed no abnormal findings. 
Results for chest radiograph, Holter electrocardiogram, 
and electroencephalogram were unremarkable. There 
were no abnormal ophthalmologic findings. Computed 
tomography of the brain showed a hypodense lesion at 
the left frontal lobe (Figure, panel A). Subsequent mag-
netic resonance imaging showed that the lesion (mass) 
was hypointense by gadolinium-enhanced, axial, T1-
weighted imaging (Figure, panel B), hyperintense by 
T2-weighted imaging, and surrounded by extensive ce-
rebral edema (Figure, panel C).
Symptomatic epilepsy caused by the mass was sus-
pected to have caused the loss of consciousness. This con-
clusion was based on the intracranial mass, long duration of 
loss of consciousness, increase in creatine kinase level (471 
U/L), and tongue bite.
When the HIV-1 infection was diagnosed in the pa-
tient 15 months earlier, results of serum rapid plasma re-
agin (RPR) and Treponema pallidum hemagglutination test 
(TPHA) were negative. However, during this examination, 
serum RPR and TPHA titers were 1:32 and 1:10,240, re-
spectively. Results of cerebrospinal fluid (CSF) analysis 
were compatible with neurosyphilis (4,5) and showed a 
leukocyte count of 35 cells/mL (2 neutrophils/mL, 33 lym-
phocytes/mL), a total protein level of 30 mg/dL, a glucose 
level of 59 mg/dL (serum glucose level 92 mg/dL), an 
RPR titer of 1:<1, a TPHA titer of 1:160, and a fluorescent 
treponemal antibody-absorption titer of 1:32.
Cerebral syphilitic gumma was suspected on the ba-
sis of neurosyphilis and compatible imaging findings (6) 
and because other conditions, such as meningioma, pri-
mary central nervous system lymphoma, toxoplasmosis, 
1846 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016
LETTERS
